The presence of leukaemia-associated phenotypes is an independent predictor of induction failure in acute myeloid leukaemia

International Journal of Laboratory Hematology

Volumn 31, Issue 1, 2009, Pages 61-68

  Al Mawali, A ^a   To, L B ^b   Gillis, D ^c   Hissaria, P ^c   Mundy, J ^c   Lewis, I ^c  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

Author keywords

Acute myeloid leukaemia; Immunophenotyping; Leukaemia associated phenotypes; Lineage infidelity; Multiparameter flow cytometry

Indexed keywords

CD15 ANTIGEN; CD34 ANTIGEN; CD56 ANTIGEN; CYTARABINE; ETOPOSIDE; IDARUBICIN; LEUKEMIA ANTIGEN; RETINOIC ACID; STEM CELL FACTOR RECEPTOR;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER RELAPSE; CELL LINEAGE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; TREATMENT PLANNING;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; REMISSION INDUCTION; RISK FACTORS; TREATMENT FAILURE; YOUNG ADULT;

EID: 58649119381     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2007.01003.x     Document Type: Article

References (30)

1. Andrews R.G., Torok-Storb B. Bernstein I.D. (1983) Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood 62, 124 132.
2. Bahia D.M., Yamamoto M., Chauffaille Mde L., Kimura E.Y., Bordin J.O., Filgueiras M.A. Kerbauy J. (2001) Aberrant phenotypes in acute myeloid leukemia: a high frequency and its clinical significance. Haematologica 86, 801 806.
3. Buccisano F., Maurillo L., Del Poeta G., Gattei V., Amadori S. Venditti A. (2006) Optimal post-remission therapy for flow-cytometry minimal residual disease positive adult patients with acute myeloid leukemia. Haematologica 91, ELT14.
4. Buchner T., Hiddemann W., Berdel W.E., Wormann B., Schoch C., Fonatsch C., Loffler H., Haferlach T., Ludwig W.D., Maschmeyer G., Staib P., Aul C., Gruneisen A., Lengfelder E., Frickhofen N., Kern W., Serve H.L., Mesters R.M., Sauerland M.C. Heinecke A. (2003) 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group. Journal of Clinical Oncology 21, 4496 4504.
5. Campana D. Coustan-Smith E. (1999) Detection of minimal residual disease in acute leukemia by flow cytometry. Cytometry 38, 139 152.
6. Campana D. Pui C.H. (1995) Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 85, 1416 1434.
7. Cheson B.D., Bennett J.M., Kopecky K.J., Buchner T., Willman C.L., Estey E.H., Schiffer C.A., Doehner H., Tallman M.S., Lister T.A., Lo-Coco F., Willemze R., Biondi A., Hiddemann W., Larson R.A., Lowenberg B., Sanz M.A., Head D.R., Ohno R. Bloomfield C.D. (2003) Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Journal of Clinical Oncology 21, 4642 4649.
8. Del Poeta G., Stasi R., Venditti A., Cox C., Aronica G., Masi M., Bruno A., Simone M.D., Buccisano F. Papa G. (1995) CD7 expression in acute myeloid leukemia. Leukaemia & Lymphoma 17, 111 119.
9. Hosmer D.W. Lemeshow S. 2000) Applied logistic regression. In Wiley Sciences in Probability and Statistics, 2nd edn. John Wiley & Son, Inc., New York.
10. Galland F., Karamysheva A., Pebusque M.J., Borg J.P., Rottapel R., Dubreuil P., Rosnet O. Birnbaum D. (1993) The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor. Oncogene 8, 1233 1240.
11. Griffin J.D., Mayer R.J., Weinstein H.J., Rosenthal D.S., Coral F.S., Beveridge R.P. Schlossman S.F. (1983) Surface marker analysis of acute myeloblastic leukemia: identification of differentiation-associated phenotypes. Blood 62, 557 563.
12. Griffin J.D., Davis R., Nelson D.A., Davey F.R., Mayer R.J., Schiffer C., McIntyre O.R. Bloomfield C.D. (1986) Use of surface marker analysis to predict outcome of adult acute myeloblastic leukemia. Blood 68, 1232 1241.
13. Grimwade D., Walker H., Oliver F., Wheatley K., Harrison C., Harrison G., Rees J., Hann I., Stevens R., Burnett A. Goldstone A. (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92, 2322 2333.
14. Grimwade D., Walker H., Harrison G., Oliver F., Chatters S., Harrison C.J., Wheatley K., Burnett A.K. Goldstone A.H. (2001) The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 98, 1312 1320.
15. Lacombe F., Durrieu F., Briais A., Dumain P., Belloc F., Bascans E., Reiffers J., Boisseau M.R. Bernard P. (1997) Flow cytometry CD45 gating for immunophenotyping of acute myeloid leukemia. Leukemia 11, 1878 1886.
16. Lowenberg B., Downing J.R. Burnett A. (1999) Acute myeloid leukemia. New England Journal of Medicine 341, 1051 1062.
17. Macedo A., Orfao A., Ciudad J., Gonzalez M., Vidriales B., Lopez-Berges M.C., Martinez A., Landolfi C., Canizo C. San Miguel J.F. (1995a) Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease. Leukemia 9, 1896 1901.
18. Macedo A., Orfao A., Vidriales M.B., Lopez-Berges M.C., Valverde B., Gonzalez M., Caballero M.D., Ramos F., Martinez M., Fernandez-Calvo J., Martinez A. San Miguel J.F. (1995b) Characterization of aberrant phenotypes in acute myeloblastic leukemia. Annals of Hematology 70, 189 194.
19. Maurillo L., Buccisano F., Spagnoli A., Poeta G.D., Panetta P., Neri B., Principe M.I.D., Mazzone C., Consalvo M.I., Tamburini A., Ottaviani L., Fraboni D., Sarlo C., Fabritiis P.D., Amadori S. Venditti A. (2007) Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. Haematologica 92, 605 611.
20. Norgaard J.M., Olesen L.H., Olesen G., Meyer K., Kristensen J.S., Bendix K., Pedersen B., Kjeldsen E. Hokland P. (2001) FAB M4 and high CD14 surface expression is associated with high cellular resistance to Ara-C and daunorubicin: implications for clinical outcome in acute myeloid leukaemia. European Journal of Haematology 67, 221 229.
21. Raspadori D., Damiani D., Lenoci M., Rondelli D., Testoni N., Nardi G., Sestigiani C., Mariotti C., Birtolo S., Tozzi M. Lauria F. (2001) CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 15, 1161 1164.
22. Reading C.L., Estey E.H., Huh Y.O., Claxton D.F., Sanchez G., Terstappen L.W., O'Brien M.C., Baron S. Deisseroth A.B. (1993) Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood 81, 3083 3090.
23. San Miguel J.F., Gonzalez M., Canizo M.C., Anta J.P., Zola H. Lopez Borrasca A. (1986) Surface marker analysis in acute myeloid leukaemia and correlation with FAB classification. British Journal Haematology 64, 547 560.
24. San Miguel J.F., Martinez A., Macedo A., Vidriales M.B., Lopez-Berges C., Gonzalez M., Caballero D., Garcia-Marcos M.A., Ramos F., Fernandez-Calvo J., Calmuntia M.J., Diaz-Mediavilla J. Orfao A. (1997) Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood 90, 2465 2470.
25. San Miguel J.F., Ciudad J., Vidriales M.B., Orfao A., Lucio P., Porwit-MacDonald A., Gaipa G., van Wering E. van Dongen J.J. (1999) Immunophenotypical detection of minimal residual disease in acute leukemia. Critical Reviews in Oncology/Hematology 32, 175 185.
26. Schoch C., Haferlach T., Haase D., Fonatsch C., Loffler H., Schlegelberger B., Staib P., Sauerland M.C., Heinecke A., Buchner T. Hiddemann W. (2001) Patients with de novo acute myeloid leukaemia and complex karyotype aberrations show a poor prognosis despite intensive treatment: a study of 90 patients. British Journal Haematology 112, 118 126.
27. Smith F.O., Lampkin B.C., Versteeg C., Flowers D.A., Dinndorf P.A., Buckley J.D., Woods W.G., Hammond G.D. Bernstein I.D. (1992) Expression of lymphoid-associated cell surface antigens by childhood acute myeloid leukemia cells lacks prognostic significance. Blood 79, 2415 2422.
28. Terstappen L.W., Konemann S., Safford M., Loken M.R., Zurlutter K., Buchner T., Hiddemann W. Wormann B. (1991) Flow cytometric characterization of acute myeloid leukemia. Part 1. Significance of light scattering properties. Leukemia 5, 315 321.
29. Tiftik N., Bolaman Z., Batun S., Ayyildiz O., Isikdogan A., Kadikoylu G. Muftuoglu E. (2004) The importance of CD7 and CD56 antigens in acute leukaemias. International Journal of Clinical Practice 58, 149 152.
30. Voskova D., Valekova L., Fedorova J., Hudecek J. Kubisz P. (2003) Leukemic cells and aberrant phenotypes in acute leukemia patients: a flow cytometry analysis. Neoplasma 50, 422 427.